This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Globus Medical (GMED) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
RDNT Stock Up Following the New Tie-Up to Leverage Radiology AI
by Zacks Equity Research
RadNet's latest collaboration aims to create an AI control system for image interpretation to ensure AI scalability, performance monitoring and safety.
GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging
by Zacks Equity Research
GE HealthCare announces the new Sonic DL for 3D, which will reduce scan times and provide faster, high-quality imaging for the majority of MR scans.
Reasons to Add Phibro Stock to Your Portfolio Right Now
by Zacks Equity Research
PAHC's Animal Health business, along with flourishing Mineral Nutrition and Performance Product businesses, sparks optimism for future growth.
3 Reasons Why Growth Investors Shouldn't Overlook Globus Medical (GMED)
by Zacks Equity Research
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GMED vs. PEN: Which Stock Is the Better Value Option?
GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care
by Zacks Equity Research
The latest collaboration aims to provide new opportunities to improve cancer diagnosis using GE HealthCare's technology and enhance clinical workflow.
Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues
by Zacks Equity Research
Abbott has a unique opportunity to scale a capital-efficient licensing model that can help the emerging market population access life-changing medicines.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
QGEN Stock to Gain From Expanding QIAstat-Dx With New Barcelona Site
by Zacks Equity Research
QIAGEN's new Barcelona site is set to drive QIAstat-Dx's growth in infectious diseases and precision medicine testing.
MDT Stock May Gain Following the Positive Data From Optimize PRO Study
by Zacks Equity Research
Medtronic announces new positive data for its Evolut TAVR from the Optimize PRO clinical research.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
by Zacks Equity Research
The FDA application complements recent label extension submissions to the EMA and Health Canada, highlighting Valneva's strategic push to enhance IXCHIQ's global reach.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Hologic to Debut AI-Powered Innovations at RSNA 2024: Stock to Gain?
by Zacks Equity Research
HOLX will unveil breakthrough innovations at this year's RSNA, focusing on imaging solutions and AI.
GEHC Stock May Gain Following the Launch of Pristina Via System
by Zacks Equity Research
GE HealthCare announces the Pristina Via mammography system, which will help minimize repetitive tasks and streamline workflows for mammography technologists.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its strong segmental performance and improved operating margin.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
New Evidence on SAPIEN 3 Ultra RESILIA Valve Set to Boost EW Stock
by Zacks Equity Research
Edwards' SAPIEN 3 Ultra RESILIA Valve continues to deliver excellent outcomes for patients in real-world data.
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
by Zacks Equity Research
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
MMSI Stock Down Despite Latest Positive Data From WRAPSODY WAVE Trial
by Zacks Equity Research
The significant improvement in patency rates for AVG patients via Merit Medical's WRAPSODY device is expected to enhance patients' vascular access survival.
BSX Stock Set to Gain From Agreement to Acquire Intera Oncology
by Zacks Equity Research
Boston Scientific's new buyout is set to expand its interventional oncology offerings.
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
by Zacks Equity Research
ISRG's strength in robotics continues to raise optimism among investors.
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects?
by Zacks Equity Research
TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine.
GEHC Stock May Gain on Its Enhanced OEC 3D Mobile CBCT C-Arm Portfolio
by Zacks Equity Research
GE HealthCare announces the latest application additions to its OEC 3D mobile CBCT C-arm portfolio to improve clinician workflow and visualization during endoscopic bronchoscopy procedures.